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Abstract: 46 
Objective: To evaluate the uptake and effectiveness of an existing open access lifestyle 47 
intervention forged in collaboration between a third sector organisation, funded by local 48 
government and a secondary care non-alcoholic fatty liver disease (NAFLD) service in the 49 
North West of England. 50 
Method: A service outcome evaluation using pre-post comparison design was conducted to 51 
analyse changes between baseline clinical health records and 12 week follow up for NAFLD 52 
patients who completed the lifestyle intervention. Lifestyle factors, weight loss, changes in 53 
alanine aminotransferase (ALT) enzymes and lipid profiles were compared between patients 54 
who completed the programme versus 1:1 matched patients who did not. 55 
Results: Only 16 of 167 NAFLD patients offered the intervention completed the programme. 56 
Intervention patients achieved significant weight loss (-2.3% p ≤ 0.05) over 12 weeks, where 57 
the non-intervention group had non-significant weight gain (+0.95%). ALT improved by 58 
20IU/L in the interventional group and 15 IU/L in the non-intervention group; however, this 59 
was not statistically different. 60 
Conclusion: This study presents first of its kind evaluation of a service collaboration in the 61 
UK. Only 1 in 10 patients offered the opportunity completed the programme, a limitation that 62 
could affect future strategies. Patient and public involvement research is needed to identify 63 
barriers to participation, address adherence issues and identify support mechanisms for lifestyle 64 
interventions with NAFLD patients.  65 
  66 
Short summary: 67 
1. What is already known about this subject? 68 
 Non-alcoholic fatty liver disease (NAFLD) represents a looming public health crisis 69 
with estimated prevalence of 20-30% of the population and younger generations 70 
increasingly becoming affected.  71 
 Lifestyle intervention is the first line treatment; however, participation rates are low in 72 
NAFLD patients and there is a lack of available localised support schemes.  73 
2. What are the new findings? 74 
 This study presents a first of its kind service evaluation of a collaboration in the UK 75 
successfully providing a privately delivered, open access lifestyle training programme 76 
funded by local government and embedded in a secondary care NAFLD care 77 
pathway.  78 
 Less than 10% of patients offered the intervention completed the 12 week program. 79 
NAFLD patients in the lifestyle intervention group achieved significant weight loss (-80 
2.3% p ≤ 0.05) coupled with significant improvements to body mass index (BMI) (-81 
0.76 kg/m2 p ≤ 0.05).  82 
 Alanine aminotransferase (ALT) enzyme levels improved by 20IU / L, however this 83 
was not significant, possibly due to the short study duration.  84 
3. How might it impact on clinical practice in the foreseeable future? 85 
 Second tier weight management service providers may offer value in specific patient 86 
cohorts, such as those with NAFLD. However, prior to commissioning services such as 87 
lifestyle training more research is needed into the reasons for its low uptake in NAFLD 88 
patients and to consider holistic behavioural modification to increase the effectiveness 89 
of intervention programmes. 90 
Keywords: Non-alcoholic fatty liver disease, lifestyle intervention, weight loss, alanine 91 
aminotransferase enzyme, lipid profiles 92 
 93 
INTRODUCTION 94 
Non-alcoholic fatty liver disease (NAFLD) represents a looming public health crisis and during 95 
the next decade is expected to become the primary cause of end stage liver disease and 96 
transplantation1. Lifestyle intervention is the first line treatment for NAFLD patients, however 97 
there is a lack of available localised support schemes and intervention participation rates are 98 
low in NAFLD patients2 3.  99 
 100 
Estimated prevalence of NAFLD in the general British population is 20-30% with younger 101 
generations increasingly becoming affected2. NAFLD occurs due to accumulation of liver fat 102 
(steatosis) usually as a consequence of the metabolic syndrome (MetS), a combination of 103 
insulin resistance, dyslipidaemia, obesity and hypertension leading to generation of lipotoxic 104 
intermediates, and a cycle of liver cell stress, inflammation and fibrosis4. Approximately one 105 
in five people (5% of the population) who have NAFLD will go on to develop the more serious 106 
non-alcohol related steatohepatitis (NASH), where the liver becomes inflamed2 5. Progression 107 
to cirrhosis, the most serious stage of NAFLD has increased dramatically over the last 10 years. 108 
NAFLD is evolving to become the commonest cause for hepatocellular cancer (HCC) and liver 109 
transplant in the western world6.  110 
 111 
Obesity is closely associated with NAFLD and NHS spending on conditions linked to obesity 112 
reached more than £6.05bn per annum in 20177. NAFLD and NASH are typically 113 
asymptomatic and medical attention is frequently devoted to the other associated features of 114 
MetS including obesity, insulin resistance, type 2 diabetes, hyperlipidaemia and hypertension, 115 
which also affect prognosis, increasing the risk of cardiovascular mortality in this group of 116 
patients4. In fact, mortality in patients with NAFLD is predominantly due to non-hepatic 117 
comorbidity. Coupled with obesity related comorbidities there are clear associations of NASH 118 
with increased risk of cardiovascular disease (CVD), cerebrovascular disease8, malignancy9, 119 
and abnormal lipoprotein subclasses8 10. In addition, emerging evidence suggests links to poor 120 
coronavirus disease 19 (COVID-19) outcomes in NAFLD patients possibly linked to immune 121 
dysregulation both intrahepatic and extrahepatic with a higher risk of progression to severe 122 
COVID-19 and longer viral shedding time in a cohort of 202 COVID-19 patients studied in 123 
China11. 124 
 125 
Lifestyle modification to lose 7-10% of total body weight by diet and exercise is the first line 126 
treatment for NAFLD2 6 12, however evidence suggests that 50% of patients do not adhere to 127 
lifestyle interventions13-15. Coupled with this a lack service provision for the management of 128 
MetS and the need for improved access to lifestyle interventions were identified as key issues 129 
in a cross-sectional survey of 175 UK gastroenterologists and hepatologists regarding NAFLD 130 
diagnosis and management4. The long term NHS plan of universalised personalised care16 131 
using social prescribing to improve access to better lifestyle has not yet found its roots and the 132 
delivery of such a system may take some time to set up. Some local authorities in England 133 
commission second tier weight management services and whilst their value in reducing the 134 
prevalence of obesity in the general population is unclear17, they may offer value in specific 135 
patient cohorts, such as those with NAFLD.  136 
Moreover, they present an opportunity for the NHS to collaborate with non-healthcare 137 
organisations and private sector companies to optimise outcomes for this patient cohort. 138 
 139 
The aim of this study was to evaluate the uptake and effectiveness of an existing open access 140 
lifestyle intervention forged out of a collaboration between a privately run lifestyle intervention 141 
service, funded by local government and a secondary care NAFLD service based in the North 142 
West of England. 143 
 144 
METHODS 145 
Participants and Design 146 
A service outcome evaluation using pre-post comparison design was conducted to analyse 147 
changes between first visit clinical health records and after 12 weeks follow up for NAFLD 148 
patients who were offered and completed the lifestyle intervention to determine if 149 
improvements occurred. The study evaluated an existing programme of lifestyle intervention 150 
in a secondary care clinic as part of a care pathway for NAFLD management. All patients 151 
attending a dedicated multidisciplinary NAFLD clinic at the Royal Liverpool and Broadgreen 152 
University Hospitals NHS Trust from April 2018 to March 2019 were offered a referral to a 153 
lifestyle trainer programme funded by Liverpool Council. The diagnosis of NAFLD was made 154 
in a pragmatic real world setting using a combination of non-invasive blood test and 155 
biomarkers, negative imaging, values of controlled attenuation parameter (CAP) obtained at 156 
liver stiffness measurements and/or histology and in the absence of excessive and/or harmful 157 
alcohol consumption (equating to less than 14 units of alcohol per week for men and women18) 158 
and secondary causes for fatty liver disease.   159 
The lifestyle intervention programme involved the patient seeing a health trainer in community 160 
hubs or GP practices weekly or fortnightly for 12 weeks. Personalised advice and support was 161 
offered to complete objectives in a Personalised Health Plan (PHP) based on Public Health 162 
England (PHE) guidelines19. The PHP had a holistic approach towards wellbeing, and 163 
examined patients eating; drinking and smoking habits; physical fitness, self-confidence; 164 
starting weight and height were also measured. Guidance and recommendations followed PHE 165 
Guidelines (e.g. Physical activity guidelines19 for adults and The Eatwell Guide20), and aimed 166 
to bring patients lifestyles closer to the guideline recommendations. Patients were asked to 167 
record everything they consumed in a 7-day estimated intakes food diary during the weeks 168 
prior to baseline and study endpoint21. Patients were asked to rank their emotional wellbeing 169 
on a scale of 0 to 100 and key health indicators such as BMI; consumption of fruit, vegetables, 170 
dairy products and fried foods were recorded at baseline and endpoint. Weight loss, changes in 171 
alanine aminotransferase (ALT) enzymes and lipid profiles were compared between patients 172 
who completed the programme and matched patients who did not.  173 
 174 
An equal sized control group of age and sex matched patients (Table 1) who were offered but 175 
did not opt in to the programme were selected with a 1:1 ratio to measure naturally occurring 176 
changes not caused by the intervention. The group that did not take part in the intervention 177 
were not aware their biochemistry would be compared to the group that completed the 178 
intervention although they did visit the clinic at the same time points and duration. Clinical 179 
health record data was collected for both groups at baseline visit and at the 12 week follow up. 180 
 181 
Data analysis  182 
Anonymised data was analysed using Statistical Package for the Social Sciences (SPSS), 183 
version 26 (IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp) 184 
statistical software.  185 
RESULTS 186 
Lifestyle intervention was offered to 167 NAFLD patients. A total of 16 (9.6%, 95% CI 6% - 187 
15%) patients completed the 12 week programme. Median age of the intervention cohort was 188 
58 years, half the cohort were female. There were no significant differences between the 189 
intervention and non-intervention (control) groups with regards to age, sex, weight, total 190 
cholesterol, triglycerides and ALT (Table 1) 191 
 192 
Table 1 - Demographic data, anthropometric variables, metabolic syndrome parameters, and 193 
ALT levels for intervention and non-intervention patients at baseline.  194 
 
Intervention (n=16) Non-intervention (n=16) P 
Age (y)† 53.50 ± 14.17 52.81 ± 13.18 0.836 
Male/female‡ 8/8 8/8 1.00 
Initial weight (kg) 105.09 ± 24.61 97.96 ± 24.46 0.213 
TC (mmol/L) 4.68 ± 1.83 4.45 ± 0.93 0.594 
TGL (mg/dL) 3.7 ± 5.28 2.35 ± 2.28 0.462 
ALT (IU/L) 76.27 ± 69.41 79.63 ± 117.86 0.187 
TC, total cholesterol; TGL, triglyceride; ALT alanine aminotransferase. Values are expressed 195 
as mean ± SD. † Mann-Whitney test. ‡Chi-square test; P < 0.05*. 196 
 197 
NAFLD patients in the intervention group achieved significant weight loss (-2.3% p ≤ 0.05) 198 
coupled with significant improvements to BMI (-0.76 kg/m2 p ≤ 0.05) over the study duration 199 
in comparison to baseline measurements whilst the non-intervention group were noted to have 200 
non-significant weight gain (+0.95%). A reduction in ALT was noted in both groups (- 20.6 201 
IU/L vs -15.75 IU/L p = 0.579) but this was non-significant compared to baseline and between 202 
groups. Similarly, there was no impact of the intervention or weight loss on the total cholesterol 203 
or triglyceride levels pre and post intervention (Tables 1, 2 and 3).  204 
Table 2 - Comparison of weight loss, changes in lipid profile and ALT levels for intervention 205 
and non-intervention patients 206 
TC, total cholesterol; TGL, triglyceride; ALT, alanine aminotransferase. Values are expressed 207 
as mean ± SD. *P ≤ 0.05 (Wilcoxon signed rank test). 208 
 209 
  210 
 
Intervention (n=16) Non-intervention (n=16) P 
Weight (kg) 2.78 ± 3.98 -0.95 ± 2.47 0.021* 
TC (mmol/L) 0.22 ± 1.04 0.07 ± 0.36 0.665 
TGL (mg/dL) 0.18 ± 1.03  -0.8 ± 0.49 0.456 
ALT (IU/L) 20.60 ± 46.58 15.75 ± 47.67 0.451 







Baseline Final P Baseline Final P 
Weight (kg) 105.09 ± 24.61 102.68 ± 25.50 0.008** 97.96 ± 24.46 98.91 ± 25.87 0.421 
TC (mmol/L) 4.68 ± 1.83 4.46 ± 1.6 0.396 4.45 ± 0.93 4.37 ± 1.01 0.359 
TGL (mg/dL) 3.7 ± 5.28 3.51 ± 4.7 0.675 2.35 ± 2.28 2.43 ± 1.97 0.279 
ALT (IU/L) 76.27 ± 69.41 55.67 ± 35.4 0.187 79.63 ± 117.86 63.88 ± 74.76 0.451 
TC, total cholesterol; TGL, triglyceride; ALT, alanine aminotransferase. Values are expressed as mean ± SD. P < 0.05* P ≤ 01**, P ≤ 0.001*** 212 
(Wilcoxon signed rank test). 213 
 214 
  215 
In terms of patient lifestyles and behaviours, significant improvements were noted for general 216 
emotional health score and fruit intake, alongside significant reductions in fried food intake (p 217 
≤ 0.05) at the end of the 12 week intervention. Improvements in importance of healthy eating 218 
scores were approaching significance, patients improved minutes of light exercise by 69 (± 219 
51.87) minutes per week (not significant) but did not increase their vegetable intake (Table 4). 220 
 221 
Table 4 - Comparison of intervention patients baseline and final lifestyle data 222 
 Baseline (n=16) Final (n=16) P 
General emotional health (score)  56.25  ± 15.43 75.38 ± 7.76 0.003** 
BMI (kg/m2) 34.15 ± 7.09 33.39 ± 7.89 0.018* 
Importance of healthy eating 
(score) 
74.66 ± 16.41 80 ± 18.70 0.053 
Fruit intake (portions/day) 0.55 ± 0.39 1.05 ± 0.49 0.006** 
Vegetable intake (portions/day) 1.15 ± 1.08 1.1 ± 0.9 0.888 
Fried food intake (portions/day) 0.35 ± 0.5 0.15 ± 0.16 0.017* 
Light Exercise (mins/week) 143 ± 132.66 212 ± 159.56 0.102 
Values are expressed as mean ± SD. P < 0.05* P ≤ 0.01** (Wilcoxon signed rank test). 223 
 224 
  225 
DISCUSSION 226 
This study presents a first of its kind service evaluation of a collaboration in the UK 227 
successfully integrating a privately delivered, open access lifestyle training programme funded 228 
by local government and embedded in a secondary care NAFLD care pathway. The study 229 
involved 167 patients offered lifestyle intervention of whom only 16 (9.58%, 95% CI 6% - 230 
15%) completed the 12 week intervention representing a 1 in 10 participation rate. Weight loss 231 
in the intervention group was significantly different to the control group (- 2.79 Kg vs + 0.95 232 
Kg, equating to 2.3% of baseline weight, p = 0.008) and led to improvements in BMI. A drop 233 
in ALT was noted in both groups though this was not statistically significant (- 20.6 IU/L vs -234 
15.75 IU/L p = 0.579). Similar published studies to this one have successfully reported positive 235 
impacts of interventions using small numbers of NAFLD patients22 23.   236 
 237 
Lack of uptake and non-adherence with interventions appears to be a consistent problem 238 
amongst NAFLD patients. Although all require lifestyle and dietary intervention, less than 50% 239 
will readily accept the need for this and fewer numbers will agree to take part and complete a 240 
designed intervention programme13 23. This may in part be due to the asymptomatic nature of 241 
both NAFLD and NASH2. Although participant uptake and recruitment is not well evidenced, 242 
some recent literature mirrors the intervention uptake issues encountered in this study. 243 
Kenneally, et al. 24 noted small sample sizes for the majority of studies identified in a systematic 244 
review of nutrition interventions in NAFLD patients. The authors found weight loss by energy 245 
restriction leads to an improvement in NAFLD but further clarification is needed as trials were 246 
heterogeneous with large variations in participant numbers and duration. NAFLD patients are 247 
18–20 % more likely to report poor physical health or are unable to perform daily activities 248 
compared to healthy controls. Besides fatigue, NAFLD patients may also experience other 249 
symptoms such as anxiety, depression, cognitive impairment, and loss of self-esteem13 25. 250 
These symptoms significantly impact patients well-being and health-related quality of life26 251 
which in turn, may affect the implementation of dietary recommendations or other self-252 
management advice.  253 
 254 
Significant weight loss was achieved by patients completing this 12 week intervention, 255 
however long term energy and weight control is challenging for many NAFLD patients13. The 256 
success of shorter term lifestyle interventions may not be sustained over longer periods after 257 
the interventions end without targeted support and follow up27. Ultimately, patients with 258 
NAFLD are required to self-manage their diet and behaviour. The long term, larger scale 259 
evidence on lifestyle intervention and dietary management for those with this condition is 260 
conflicting28. Prior to any further larger scale long term trials, a patient and public involvement 261 
research approach may be useful to establish potential barriers to lifestyle and dietary 262 
interventions in NAFLD patients. This would then inform the design of powered, longer-term 263 
large-scale lifestyle interventions in greater numbers of NAFLD patients with the provision of 264 
regular medical support from clinicians, dietitians, nutritionists and health trainers, which may 265 
lead to further improvements in the parameters measured in this study. 266 
 267 
Reductions in ALT were noted in both groups, ALT improved by 20IU / L in the intervention 268 
group and 15 IU / L in the control group, over the 12 week period but these did not reach 269 
statistical significance. This may be due to the small sample size and a possible Type II error. 270 
The lifestyle intervention patients did increase their exercise levels by 69 minutes (± 51.87) per 271 
week over the study duration. The exact mechanisms of how exercise and weight loss may 272 
improve NAFLD are not well understood, but regular exercise may change body composition 273 
leading to decreased fat mass without overall weight loss24. Alcohol intake is regularly assessed 274 
for all patients in the fatty liver clinic and patients with alcohol consumption higher than 14 275 
units per week were excluded from this study sample. However, it is possible that even further 276 
reductions in alcohol consumption within these limits were made by some patients during the 277 
study period which may have contributed to improved ALT levels in both groups. Dietary 278 
intakes and exercise levels were not recorded for the control group, therefore it is possible 279 
independent lifestyle changes such as taking regular exercise may have been made, which in 280 
turn could also lead to the small reductions in ALT for this group in the absence of weight loss. 281 
Finally, regular follow up for all patients in a dedicated fatty liver clinic where soft outcomes 282 
such as improvements in liver biochemistry which are visible and tangible benefits are 283 
commonly discussed might have impacted the results and introduced a bias. Whilst this 284 
suggests that the fatty liver clinic is promoting a healthier lifestyle in patients, it presents a 285 
potential to confound the results. However, the group that did not take up the intervention were 286 
not aware that their biochemistry would be compared to the group that completed the 287 
intervention. 288 
 289 
A small but significant increase in fruit by 61.7%, but not vegetable intake was noted in the 290 
current study, however overall fruit and vegetable consumption (baseline 0.55 ± 0.39 and 291 
endpoint 1.05 ± 0.49 (p = 0.006) for fruit and baseline 1.15 ± 1.08 and endpoint 1.1 ± 0.9 (NS) 292 
for vegetables respectively) fell far short of both national population averages (4.2 portions)29 293 
and the recommended 5 portions a day20. There was a reduction in the use of fried food and 294 
snacking by 13% and 21% respectively. Unfortunately these improvements did not translate to 295 
patients lipid profiles and there were no significant changes to total cholesterol and blood 296 
triglycerides at the end of the study, which may be due to the short study duration. Full 297 
nutritional evaluation of the 7-day estimated food intakes was not completed; this is a limitation 298 
that should be addressed in future studies. 299 
Completing the programme was associated with an improvement in self-rated emotional 300 
wellbeing (56.25% to 75%). A mean increase to general emotional health scores (19% ± 4.31) 301 
was noted for the patients completing the intervention showing a significant positive effect on 302 
general well-being (p = 0.003). This may be linked to the use of lifestyle trainers to support 303 
patients during the intervention and coupled with previous evidence30 31 suggests lifestyle 304 
interventions with a well-being support element may offer an effective strategy in the treatment 305 
of NAFLD.  306 
 307 
This pragmatically conducted, real world service evaluation exercise provides important 308 
preliminary data to evaluate the efficacy of an existing open access lifestyle intervention in 309 
NAFLD patients. However, there are limitations, which must be considered. The 16 patients 310 
that took part represented only 1 in 10 patients offered the intervention. Poor uptake of the 311 
lifestyle intervention and subsequent small sample size limits the efficacy of comparison 312 
between the intervention and the control groups. Coupled with low participation and 313 
recruitment rates in NAFLD patients discussed earlier intervention recruitment may have been 314 
limited by selection bias. Vilar-Gomez, et al. 32 conducted a 52-week long intensive 315 
intervention with 293 NASH patients who agreed to have paired biopsies and had reasonable 316 
control of metabolic parameters such as HBA1C. With this elaborate lifestyle intervention 317 
program, 30% of patients lost more than 5% of their body weight and 25% achieved resolution 318 
of steatohepatitis. The uptake of the intervention was reported at 96% though it is important to 319 
note that the study was designed to assess the histological impact of intervention. Even with 320 
comprehensive intervention in this selected motivated cohort of patients only 30% achieved 321 
weight loss of > 5% which reflects the real world challenges faced by patients and their 322 
healthcare providers in achieving weight loss. Whilst histological improvement was not seen 323 
in all patients, the reported impact of lifestyle intervention in terms of NASH resolution was 324 
comparable to the efficacy reported from pharmacotherapy for NASH currently being 325 
recommended33 or approved for use in NASH34. The limited number of patients that took part 326 
in our lifestyle intervention are likely to have been motivated to make changes, where the 327 
matched control group were not.  Whilst both groups received regular follow up in the NAFLD 328 
clinic with ongoing advice and encouragement to address lifestyle in clinic, the intervention 329 
group benefited from additional focussed support provided by trained lifestyle health trainers 330 
for 12 weeks. Coupled with this the 12 week study duration represents a short term intervention 331 
and may not have been long enough to see significant improvements in NAFLD biomarkers. It 332 
is important to note that this study did not evaluate the reasons for non-participation, which is 333 
a significant limitation and will be evaluated in a future planned study. 334 
 335 
In conclusion, offering lifestyle intervention in an integrated NAFLD care management 336 
pathway resulted in significant weight loss of 2.3% of baseline body weight in 16 NAFLD 337 
patients after 12 weeks with significant improvements to BMI; however, uptake was 338 
suboptimal with a participation completions rate of less than 10%. This study highlights the 339 
challenge of engaging patients to accept such a programme when offered to them in a real 340 
world setting. There was no impact of this degree of weight loss on biochemical liver indices 341 
over 12 weeks. Further well-planned research using powered randomised controlled trials of 342 
longer duration in larger cohorts of NAFLD patients is urgently needed to ratify the present 343 
findings and prior to local government commissioning lifestyle intervention services. Focused 344 
patient and public involvement research is needed to identify potential barriers to participation, 345 
address adherence issues and identify appropriate support mechanisms for lifestyle 346 
interventions with NAFLD patients. 347 
 348 
REFERENCES 349 
1. British Liver Trust. The alarming impact of liver disease in the UK - Facts and statistics. 350 
Bournemouth, UK: The British Liver Trust, 2019. 351 
2. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: 352 
Vascular diseases of the liver. J Hepatol 2016;64(1):179-202. doi: 353 
10.1016/j.jhep.2015.07.040 [published Online First: 2015/10/31] 354 
3. Dyson JK, Wong LL, Bigirumurame T, et al. Inequity of care provision and outcome 355 
disparity in autoimmune hepatitis in the United Kingdom. Aliment Pharmacol Ther 356 
2018;48(9):951-60. doi: 10.1111/apt.14968 357 
4. Sheridan DA, Aithal G, Alazawi W, et al. Care standards for non-alcoholic fatty liver disease 358 
in the United Kingdom 2016: a cross-sectional survey. Frontline Gastroenterol 359 
2017;8(4):252-59. doi: 10.1136/flgastro-2017-100806 360 
5. National Institute for Health and Care Excellence. Non-alcoholic fatty liver disease - 361 
Assessment and management. London: National Institute for Health and Care 362 
Excellence, 2016. 363 
6. Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: The impact of obesity, 364 
type 2 diabetes and a multidisciplinary team. J Hepatol 2014;60(1):110-17. doi: 365 
https://doi.org/10.1016/j.jhep.2013.08.011 366 
7. Tovey M. IEA Discussion Paper No.80, OBESITY AND THE PUBLIC PURSE - Weighing 367 
up the true cost to the taxpayer. London: Institute of Economic Affairs, 2017. 368 
8. Targher G, Day CP, Bonora E. Risk of Cardiovascular Disease in Patients with Nonalcoholic 369 
Fatty Liver Disease. N Engl J Med 2010;363(14):1341-50. doi: 370 
10.1056/NEJMra0912063 371 
9. Kim GA, Lee HC, Choe J, et al. Association between non-alcoholic fatty liver disease and 372 
cancer incidence rate. J Hepatol 2017 doi: 10.1016/j.jhep.2017.09.012 [published 373 
Online First: 2017/11/19] 374 
10. Lonardo A, Sookoian S, Pirola CJ, et al. Non-alcoholic fatty liver disease and risk of 375 
cardiovascular disease. Metabolism 2016;65(8):1136-50. doi: 376 
https://doi.org/10.1016/j.metabol.2015.09.017 377 
11. Ji D, Qin E, Xu J, et al. Implication of non-alcoholic fatty liver diseases (NAFLD) in 378 
patients with COVID-19: a preliminary analysis. J Hepatol 2020:S0168-379 
8278(20)30206-3. doi: 10.1016/j.jhep.2020.03.044 380 
12. Moore JB. From sugar to liver fat and public health: systems biology driven studies in 381 
understanding non-alcoholic fatty liver disease pathogenesis. Proc Nutr Soc 382 
2019;78(3):290-304. doi: 10.1017/S0029665119000570 [published Online First: 383 
2019/03/29] 384 
13. Yasutake K, Kohjima M, Kotoh K, et al. Dietary habits and behaviors associated with 385 
nonalcoholic fatty liver disease. World J Gastroenterol 2014;20(7):1756-67. doi: 386 
10.3748/wjg.v20.i7.1756 [published Online First: 2014/03/04] 387 
14. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic 388 
fatty liver disease in adults: a systematic review. J Hepatol 2012;56(1):255-66. doi: 389 
10.1016/j.jhep.2011.06.010 [published Online First: 2011/07/05] 390 
15. Dansinger ML, Gleason JA, Griffith JL, et al. Comparison of the Atkins, Ornish, Weight 391 
Watchers, and Zone Diets for Weight Loss and Heart Disease Risk Reduction A 392 
Randomized Trial. JAMA 2005;293(1):43-53. doi: 10.1001/jama.293.1.43 393 
16. National Health Service. The NHS Long Term Plan, 2019. 394 
17. Mears R, Jago R, Sharp D, et al. Exploring how lifestyle weight management programmes 395 
for children are commissioned and evaluated in England: a mixed methodology study. 396 
BMJ Open 2019;9(12):e025423. doi: 10.1136/bmjopen-2018-025423 397 
18. Department of Health. UK Chief Medical Officers’ Low Risk Drinking Guidelines London: 398 
Department of Heath,; 2016 [Available from: 399 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachme400 
nt_data/file/545937/UK_CMOs__report.pdf. 401 
19. Davies SC, Atherton F, McBride M, et al. UK Chief Medical Officers Physical Activity 402 
Guidelines,. London: Department for Health and Social Care, 2019. 403 
20. Public Health England. Government Dietary Recommendations. London: Public Health 404 
England,, 2016. 405 
21. National Institute for Health Research. Diet, Anthropometry and Physical Activity (DAPA) 406 
Measurement Toolkit, Cambridge2020 [Available from: https://dapa-407 
toolkit.mrc.ac.uk/diet/subjective-methods/estimated-food-diaries. 408 
22. Hamurcu Varol P, Kaya E, Alphan E, et al. Role of intensive dietary and lifestyle 409 
interventions in the treatment of lean nonalcoholic fatty liver disease patients. Eur J 410 
Gastroenterol Hepatol 2019 doi: 10.1097/meg.0000000000001656 [published Online 411 
First: 2020/02/25] 412 
23. Elias MC, Parise ER, Carvalho Ld, et al. Effect of 6-month nutritional intervention on non-413 
alcoholic fatty liver disease. Nutrition 2010;26(11):1094-99. doi: 414 
https://doi.org/10.1016/j.nut.2009.09.001 415 
24. Kenneally S, Sier JH, Moore JB. Efficacy of dietary and physical activity intervention in 416 
non-alcoholic fatty liver disease: a systematic review. BMJ Open Gastroenterol 417 
2017;4(1):e000139. doi: 10.1136/bmjgast-2017-000139 418 
25. Mahmood S, Kida T, Izumi A, et al. Assessment of health related quality of life in chronic 419 
liver disease patients using the Japanese versions of CLDQ and SF-36. Open J 420 
Gastroenterol 2008;2(1) 421 
26. Loria A, Escheik C, Gerber NL, et al. Quality of Life in Cirrhosis. Curr Gastroenterol Rep 422 
2012;15(1):301. doi: 10.1007/s11894-012-0301-5 423 
27. Pugh CJ, Sprung VS, Jones H, et al. Exercise-induced improvements in liver fat and 424 
endothelial function are not sustained 12 months following cessation of exercise 425 
supervision in nonalcoholic fatty liver disease. Int J Obes (Lond) 2016;40(12):1927-30. 426 
doi: 10.1038/ijo.2016.123 [published Online First: 2016/10/19] 427 
28. Katsagoni CN, Georgoulis M, Papatheodoridis GV, et al. Effects of lifestyle interventions 428 
on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-429 
analysis. Metabolism 2017;68:119-32. doi: 10.1016/j.metabol.2016.12.006 [published 430 
Online First: 2017/02/12] 431 
29. Roberts C, Steer T, Mablethorpe N, et al. National Diet and Nutrition Survey Results from 432 
Years 7 and 8 (combined) of the Rolling Programme (2014/2015 to 2015/2016). 433 
London: Public Health England, 2018. 434 
30. Unwin D, Cuthbertson D, Feinman R, et al. A pilot study to explore the role of a low-435 
carbohydrate intervention to improve GGT levels and HbA1c. Diabesity Prac 436 
2015;4:102-08. 437 
31. Golabi P, Otgonsuren M, Cable R, et al. Non-alcoholic Fatty Liver Disease (NAFLD) is 438 
associated with impairment of Health Related Quality of Life (HRQOL). Health Qual 439 
Life Outcomes 2016;14(1):18. doi: 10.1186/s12955-016-0420-z 440 
32. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through 441 
Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. 442 
Gastroenterol 2015;149(2):367-78.e5. doi: 443 
https://doi.org/10.1053/j.gastro.2015.04.005 444 
33. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, Vitamin E, or Placebo for 445 
Nonalcoholic Steatohepatitis. N Engl J Med 2010;362(18):1675-85. doi: 446 
10.1056/NEJMoa0907929 447 
34. Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-448 
alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-449 
controlled phase 3 trial. The Lancet 2019;394(10215):2184-96. doi: 10.1016/S0140-450 
6736(19)33041-7 451 
 452 
 453 
 454 
